CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd., has obtained marketing authorisation from UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Dazublys™, its trastuzumab biosimilar version. Earlier in July 2025, Dazublys™ has received the marketing authorisation in the European Union from the European Commission (EC). This is CuraTeQ's fourth biosimilar to be approved by MHRA after the approval of Bevqolva™ in December 2024 and Zefylti™ in May 2025 and Dyrupeg™ in June 2025. Dazublys™, Zefylti™, and Dyrupeg™ are also approved in the European Union.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1067.35 as compared to the previous close of Rs. 1050.25. The total number of shares traded during the day was 15092 in over 897 trades.

The stock hit an intraday high of Rs. 1075.00 and intraday low of 1052.55. The net turnover during the day was Rs. 16062354.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 Pharmaceuticals CuraTeQBiologics UKMHRA MarketingAuthorisation Dazublys trastuzumab BiosimilarVersion